Engineered cell lines for insulin replacement in diabetes: current status and future prospects.
The recently completed diabetes complications and control trial has highlighted the need for improvement of insulin delivery systems for treatment of insulin-dependent diabetes mellitus. Despite steady improvement in methods for islet and whole pancreas transplantation over the past three decades, the broad-scale applicability of these approaches remains uncertain due in part to the difficulty and expense associated with procurement of functional tissue. To address this concern, we and others have been using the tools of molecular biology to develop cell lines with regulated insulin secretion that might serve as a surrogate for primary islets or pancreas tissue in transplantation therapy. This article seeks to provide a brief summary of the current status of this growing field, with a particular emphasis on progress in producing cell lines with appropriate glucose-stimulated insulin secretion.
Newgard
C B
CB
Gifford Laboratories for Diabetes Research, University of Texas Southwestern Medical Center at Dallas 75235, USA.
Clark
S
S
BeltrandelRio
H
H
Hohmeier
H E
HE
Quaade
C
C
Normington
K
K
D002460:Cell Line; D017690:Cell Transplantation; D003922:Diabetes Mellitus, Type 1 / Q000517:prevention & control*; D005818:Genetic Engineering / Q000379:methods*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology* / Q000378:metabolism
D007328:Insulin